WS #15374
In the biotech and corporate sectors, Viking Therapeutics has initiated exploratory oral maintenance dosing for its dual agonist obesity drug VK2735, keeping the GLP-1 sector in focus. Robo.ai saw its stock jump 8% following a strong $600 million 2026 revenue projection, signaling continued investor appetite for AI-adjacent software growth. Meanwhile, Nomad Foods affirmed its full-year EPS guidance, providing a stable anchor in the consumer staples sector amidst broader macro uncertainty.
Biotech & Corporate Earnings
In the biotech and corporate sectors, Viking Therapeutics has initiated exploratory oral maintenance dosing for its dual agonist obesity drug VK2735, keeping the GLP-1 sector in focus. Robo.ai saw its stock jump 8% following a strong $600 million 2026 revenue projection, signaling continued investor appetite for AI-adjacent software growth. Meanwhile, Nomad Foods affirmed its full-year EPS guidance, providing a stable anchor in the consumer staples sector amidst broader macro uncertainty.